Novo Nordisk Foundation completes its board takeover

Shareholders of Novo Nordisk, the maker of semaglutide (Ozempic, Wegovy, Rybelsus), voted on Friday, Nov. 14, to install a new board chaired by former chief executive Lars Rebien Sorensen, completing a takeover of the board by the company's controlling owner, the Novo Nordisk Foundation ^[1][2].

At the extraordinary general meeting, Sorensen was elected chair, with Cees de Jong as vice chair and Britt Meelby Jensen and Stephan Engels added as members ^[1]. The revamped board secured more than 90% approval, but some key minority shareholders protested or abstained, saying too much decision-making power was being concentrated in Sorensen, who also chairs the Foundation ^[2]. That dual role is unprecedented in the company's history ^[2].

The arithmetic behind the vote explains the friction: the Foundation holds 77% of Novo Nordisk's voting rights while owning only about 28% of its share capital ^[2]. The shake-up followed the October resignation of chairman Helge Lund and six other board members, who stepped down citing disagreements with the Foundation over governance principles ^[1][2]. Sorensen has said the Foundation wanted a faster and more sweeping board renewal than the sitting board was willing to accept: "It was impossible to reach an agreement between the views of the current board and the foundation board," he said in October ^[1].

What the new chair says he wants

Sorensen, who was CEO from 2000 to 2016, told the meeting his mandate has two parts: supporting CEO Mike Doustdar's transformation plans "to regain its competitive leadership," and preparing the way for a successor ^[1]. He said he wants to stay no more than two to three years and would "like to make myself redundant as quickly as possible," after which the Foundation would return to operating at arm's length from the company ^[2].

He also signaled where the business is heading. Sorensen said he wants new directors with recent pharmaceutical or over-the-counter experience, "particularly as the company shifts toward a direct-to-consumer, cash-paying model" ^[2]. "We would like to strengthen the board with some qualifications, preferably with recent pharma experience, perhaps even OTC experience," he said ^[2].

The backdrop is a rough year. Wegovy sales growth has slowed, and competition from Eli Lilly and compounding pharmacies, along with earlier supply constraints, has eroded Novo's first-mover advantage in weight-loss drugs ^[2]. Novo Nordisk shares were down 36% year to date as of late October, according to BMO Capital Markets, and fell another 1.4% to $54.94 on the day the board changes were announced ^[1]. Doustdar is leading global layoffs that have cut thousands of jobs and entire research divisions ^[1][2], and the company entered a bidding war for obesity biotech Metsera but lost to Pfizer ^[2].

Analysts at BMO said they want to see Novo "redouble efforts" against compounders taking U.S. market share, diversify beyond the semaglutide franchise, and re-establish leadership in incretin drug development ^[1].

Why it matters for patients

Boardroom fights do not change a prescription, but they shape the choices a company makes about price, supply and how its drugs are sold. The most concrete signal for U.S. patients is the emphasis on a direct-to-consumer, cash-paying model and the chair's stated interest in over-the-counter expertise ^[2]. That suggests continued investment in channels where people pay out of pocket rather than through insurance.

It is important to be precise about what was not said. The sources describe an interest in OTC experience and a consumer-oriented business, not a filing, approval or timeline for any GLP-1 medicine to be sold without a prescription. Whether that ever happens, and what it would cost, is not yet known from these sources.

The pressure from Eli Lilly, which makes tirzepatide (Mounjaro, Zepbound), and from compounded copies is also the stated reason for the upheaval ^[1][2]. Competition of that kind can affect list prices and promotions, but the sources give no specific pricing changes.

What happens next

Sorensen said he expects to serve as chair for no more than two to three years before a successor is elected ^[1][2]. Novo Nordisk had originally planned to elect board members at its regular annual general meeting in 2026 before the Foundation forced the earlier extraordinary meeting ^[1]. No date has been set for naming a permanent successor chair.